Grifols SA (GIFLF)
11.76
0.00 (0.00%)
USD |
OTCM |
Aug 27, 16:00
Grifols Price to Book Value : 1.262 for Aug. 27, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 1.262 |
| August 26, 2026 | 1.262 |
| August 25, 2026 | 1.262 |
| August 24, 2026 | 1.262 |
| August 21, 2026 | 1.262 |
| August 20, 2026 | 1.262 |
| August 19, 2026 | 1.262 |
| August 18, 2026 | 1.262 |
| August 17, 2026 | 1.262 |
| August 14, 2026 | 1.262 |
| August 13, 2026 | 1.262 |
| August 12, 2026 | 1.262 |
| August 11, 2026 | 1.262 |
| August 10, 2026 | 1.262 |
| August 07, 2026 | 1.262 |
| August 06, 2026 | 1.262 |
| August 05, 2026 | 1.262 |
| August 04, 2026 | 1.262 |
| August 03, 2026 | 1.100 |
| July 31, 2026 | 1.100 |
| July 30, 2026 | 1.100 |
| July 29, 2026 | 1.100 |
| July 28, 2026 | 1.100 |
| July 27, 2026 | 1.100 |
| July 24, 2026 | 1.100 |
| Date | Value |
|---|---|
| July 23, 2026 | 1.100 |
| July 22, 2026 | 1.100 |
| July 21, 2026 | 1.100 |
| July 20, 2026 | 1.100 |
| July 17, 2026 | 1.100 |
| July 16, 2026 | 1.100 |
| July 15, 2026 | 1.087 |
| July 14, 2026 | 1.087 |
| July 13, 2026 | 1.110 |
| July 10, 2026 | 1.110 |
| July 09, 2026 | 1.110 |
| July 08, 2026 | 1.110 |
| July 07, 2026 | 1.126 |
| July 06, 2026 | 1.126 |
| July 02, 2026 | 1.126 |
| July 01, 2026 | 1.122 |
| June 30, 2026 | 1.122 |
| June 29, 2026 | 1.131 |
| June 26, 2026 | 1.131 |
| June 25, 2026 | 1.131 |
| June 24, 2026 | 1.131 |
| June 23, 2026 | 1.131 |
| June 22, 2026 | 1.131 |
| June 18, 2026 | 1.131 |
| June 17, 2026 | 1.131 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Pharma Mar SA | 5.887 |
| Oryzon Genomics SA | 2.186 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.21 |
| Anika Therapeutics, Inc. | 2.032 |
Price to Book Value Related Metrics
| PE Ratio | 15.17 |
| PS Ratio | 0.9241 |
| PEG Ratio | 0.246 |
| Price to Free Cash Flow | 10.63 |
| Price | 11.76 |
| Earnings Yield | 6.59% |
| Market Cap | 8.000B |
| PEGY Ratio | 0.2372 |
| Operating PE Ratio | 5.694 |
| Normalized PE Ratio | 15.17 |